share_log

Avalo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Great Point Partners, LLC(0.26%),Dr. Jeffrey R. Jay, M.D.(0.26%), etc.

SEC announcement ·  Feb 14 17:35
Summary by Moomoo AI
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more